Molina Healthcare (MOH) is back in focus after its second quarter 2026 earnings, where reported revenue of US$10,874 million and net income of US$60 million contrasted with higher figures from a year earlier.

The share price reaction has been sharp in the short term, with a 7 day share price return of down 12.34% and a 1 day move of down 1.37%. However, the 90 day share price return of 12.28% and 1 year total shareholder return of 19.71% still point to positive momentum over a longer window.

If Molina Healthcare’s latest moves have you reassessing the sector, it could be a good time to see what else is gaining attention through the 39 healthcare AI stocks

For Molina Healthcare, a sharp pullback after mixed earnings and a rebalanced index listing could signal investors reassessing the business, or simply sentiment resetting. How does the current share price stack up against the fundamentals?

Most Popular Narrative: 3% Overvalued

On the most followed narrative, Molina Healthcare’s fair value of $191.76 sits slightly below the last close of $197.55, which puts more scrutiny on the earnings path behind that estimate.

Molina's successful track record of winning RFPs, including new contracts in Nevada and Illinois, is expected to drive significant revenue growth, with projected incremental annual premium revenue of approximately $800 million. This should positively impact revenue and EPS growth.

The fair value story for Molina Healthcare leans heavily on faster premium growth, thicker margins, and a different earnings multiple than the stock trades on today. Curious which assumptions matter most and how sensitive that $191.76 figure is to revenue, margin and earnings targets over the next few years? The full narrative lays out the numbers behind that view in detail.

Result: Fair Value of $191.76 (OVERVALUED)

However, the Molina Healthcare narrative still hinges on two pressure points: potential Medicaid funding changes and higher medical costs that could squeeze margins if rate updates fall short.

Another View: Molina Healthcare Through The P/S Lens

While the most followed Molina Healthcare narrative points to fair value of $191.76 and labels the stock as slightly overvalued, the pricing picture looks different when you focus on sales. On a P/S basis around 0.2x, Molina trades well below peers at 2.1x, the US Healthcare industry at 1.4x, and even the fair ratio of 0.8x, which suggests the market could move closer to that level over time. That gap can signal either a margin of safety if the narrative proves too cautious or a value trap if profitability does not improve as expected. Which side of that trade do you think the stock belongs on?

Next Steps

With Molina Healthcare showing both pressure points and potential bright spots, it makes sense to act quickly and test the story against the numbers yourself. To see how the upside and downside stack up side by side, start with the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Molina Healthcare?

If Molina Healthcare has sharpened your thinking, do not stop there. Use the Simply Wall St screener to broaden your watchlist with fresh opportunities.

• Zero in on potential mispriced opportunities by reviewing the 49 high quality undervalued stocks before the crowd catches on.
• Strengthen your defense by checking companies in the 81 resilient stocks with low risk scores that score well on resilience and downside protection.
• Spot potential future standouts early by scanning the screener containing 20 high quality undiscovered gems that many investors may still be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.